The PI3K-AKT signaling pathway regulates cell survival, proliferation, and migration. An abnormal activation of PI3K plays an important role in cancer development. Here, we identify TRAF6 as a potent E3 ubiquitin ligase for the PI3K catalytic subunit PIK3CA (p110a). TRAF6 interacts with PIK3CA and promotes its nonproteolytic polyubiquitination under serum stimulation. TRAF6 ubiquitinates both individual and regulatory subunit-bound PIK3CA but does not ubiquitinate the regulatory subunit of PI3K. The examination of TRAF6 mRNA expression revealed its upregulation in multiple human malignancies. We demonstrate that overexpression of TRAF6 greatly enhances PI3K activation, leading to an increase in AKT phosphorylation and cell growth. We conclude that TRAF6 is a novel PIK3CA regulator whose deregulated overexpression represents a mechanism for PI3K overactivation in tumors.
via its direct binding to the activated receptor tyrosine kinases (RTKs), Ras proteins, and other adaptor proteins such as insulin receptor substrate 1 and 2 (IRS1/ 2) [1, 3, 9] . In addition, previous studies also clarified the emerging role of post-translational modifications, especially ubiquitination, in orchestrating PI3K activity. For example, two E3 ubiquitin ligases, Cbl-b and Skp1-Cul1-FBXL2, have been demonstrated to ubiquitinate the p85 regulatory subunit [10, 11] . Our previous work also demonstrated that the catalytic subunits of PI3K undergo strong ubiquitination in vivo [12] . We further identified NEDD4L (neural precursor cell expressed, developmentally downregulated 4-like) as the first PIK3CA E3 ubiquitin ligase that targets PIK3CA for proteasomal degradation [12] . The suppression of NEDD4L decreased the ubiquitination of PIK3CA under serum deprivation but did not affect PIK3CA ubiquitination under growth factor present condition, suggesting that there are other E3 ubiquitin ligases in cells that regulate PIK3CA ubiquitination in a completely different manner [12] .
Tumor necrosis factor receptor-associated factor (TRAF) proteins are a group of RING-finger type E3 ubiquitin ligases, which were initially identified as the signal transducers of tumor necrosis factor receptors (TNFRs) [13] [14] [15] [16] . They are recruited to the membrane-proximal region in response to TNFRs activation and are thought to be important for regulating cell survival and death [13] [14] [15] [16] . Given the roles of TRAF proteins in mediating the signaling transduction from many cell surface receptors and their relations with cell survival and death, we sought to answer whether TRAF proteins are E3 ubiquitin ligases for PIK3CA.
Materials and methods

Antibodies and reagents
Antibodies for PIK3CA (#4249), TRAF6 (#8028), TRAF5 (#41658), phospho-Thr308-AKT (#2965), phospho-Ser473-AKT (#9271), AKT (#9272), phospho-FOXO1/3a (#9464), FOXO3a (#12829), PARP (#9532), caspase-3 (#9668), and ubiquitin (#3933) were from Cell Signaling Technology, Inc. (Danvers, MA, USA). Antibodies for b-actin (sc-47778), HA (sc-7392), and c-Myc (sc-40, HRP-conjugated) were from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Anti-Flag M2 HRP-conjugated antibody (A8592), anti-Flag M2 affinity gel (A2220), puromycin (P7255), and phosphatase inhibitor cocktail-3 (P0044) were from MilliporeSigma (St. Louis, MO, USA). Protease inhibitor cocktail tablets (#04693116001) were from Roche Diagnostics (Indianapolis, IN, USA).
Transfection and immunoprecipitation
The cDNA-encoding human PIK3CA was cloned into a pCI vector (Promega Corporation, Madison, WI, USA). Human ubiquitin, PIK3R1, PIK3CB, and TRAF1-6 were cloned into pcDNA3.1 vectors (Thermo Fisher Scientific, Waltham, MA, USA) with the indicated tags at the N terminus. For transient overexpression, human embryonic kidney (HEK)-293T cells were seeded in 6 cm dishes at a density of 1.2 9 10 6 cells/dish, cultured overnight, and then transfected using Lipofectamine 2000 reagent. Cells were collected 24 h after transfection, washed with PBS, and lysed on ice for 15 min in 200 lL lysis buffer (20 mM HEPES, 150 mM NaCl, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 0.3% CHAPS, pH 7.5) supplemented with protease inhibitor cocktail and phosphatase inhibitor cocktail-3. Protein concentrations of cleared cell lysates were measured by bicinchoninic acid assay (Thermo Fisher Scientific). The total protein was normalized before applied to western blot or immunoprecipitation. A volume of 25 lL of 50% slurry anti-Flag M2 beads were used per IP sample. The beads were incubated with cell lysates with rotation for 2 h at 4°C, washed three times with lysis buffer, and then directly boiled with protein loading buffer. The supernatants of the boiled samples were resolved by SDS/ PAGE and analyzed by western blot. For immunoprecipitation of endogenous proteins, cleared lysates harvested from 10 cm dish cell culture were incubated with 6 lL antibody and 25 lL protein A/G beads, and processed as described above for Flag IP.
Overexpression of TRAF6 or GFP
For lentiviral-based stable overexpression, TRAF6 or GFP cDNAs were cloned into a pLVX vector (Takara, Mountain View, CA, USA). Lentivirus was produced by cotransfection of packaging plasmid pCMV-dR8.2, envelope plasmid pCMV-VSV-G, and pLVX-TRAF6/GFP into HEK293T cells. Twenty-four hours after virus transfection, the cells were selected with 1 lgÁmL À1 puromycin for 1 week for stable expression of exogenous proteins.
Serum stimulation and low serum challenges
To examine the AKT phosphorylation in response to serum stimulation, cells were seeded in 6 cm dish (2 9 10 5 cells/ dish), cultured overnight, and changed into serum-free Dulbecco's modified Eagle's medium (DMEM). Twenty-four hours later, a final concentration of 10% FBS was added to the medium. At the indicated time points, the cells were washed with 1 mL PBS, followed by addition of 100 lL lysis buffer. Cells were rapidly scraped off the dishes, lysed for 15 min on ice, and centrifuged. The cleared lysates were normalized and applied to western blot. For low serum challenges, the cells were trypsinized, washed with PBS, and directly seeded in serum-free or low-serum DMEM. Twenty-four hours later, the cells were collected and lysed. Normalized clear cell lysates were subjected to western blot analysis.
Measuring the cell growth
Cells were seeded in 10 cm dish at a density of 1 9 10 5 cells/dish. At the indicated time points, the cells were trypsinized. The number of living cells was counted by Trypan Blue staining. Cell size was measured using a Cellometer Auto T4 machine. Cell images were taken at the indicated time points under phase contrast microscopy.
Soft agar colony formation assay
Lower layer medium (1% agarose in DMEM plus 10% FBS) was first poured into 6 cm dishes (3 mL medium per dish) and cooled. The cells were mixed with the upper layer medium (0.7% agarose in DMEM plus 10% FBS) and poured in the dishes (3 mL medium per dish and 1 9 10 4 cells per dish). Finally, the upper agar layer was covered with 3 mL cell culture medium (DMEM plus 10% FBS and antibiotics) and cultured for 6 weeks before the colonies were counted.
Gel filtration analysis
The cells were depleted with serum for 24 h followed by replenishment with 10% FBS for 10 min. Then, the cells were washed with PBS and directly lysed using lysis buffer supplemented with protease and phosphatase inhibitors. The cleared cell lysates were normalized and loaded on a Superdex 200 10/ 300 GL column (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA), which was equilibrated with buffer containing 20 mM HEPES, 150 mM NaCl, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, and 0.02% CHAPS, pH 7.5. Proteins were eluted at a flow rate of 0.5 mLÁmin À1 and fractionated at 0.5 mL per tube, followed by western blot analysis.
Results
TRAF6 ubiquitinates PIK3CA in vivo
To test whether TRAF proteins can ubiquitinate PIK3CA, we coexpressed TRAF1-6, respectively, with PIK3CA in HEK-293T cells, and examined the ubiquitination states of immunoprecipitated PIK3CA. We observed that PIK3CA immunoprecipitates from TRAF6-overexpressing cells showed the strongest polyubiquitination signal, whereas the immunoprecipitates from TRAF5-and TRAF2-overexpressing cells showed relatively weak polyubiquitination (Fig. 1A , upper panel). We did not observe any ubiquitination of PIK3CA immunoprecipitates from TRAF1-, TRAF3-and TRAF4-overexpressing cells (Fig. 1A , upper panel). We examined the Flag-tagged PIK3CA in cell lysates and found that overexpression of TRAF6 led to an obvious formation of high-molecular weight shifts (Fig. 1A , middle panel, lane 7), indicating that PIK3CA is directly ubiquitinated. Moreover, we generated two previously verified TRAF6 inactive mutants [17] and coexpressed them with PIK3CA. Abolishing TRAF6 activity led to a dramatic decrease in PIK3CA polyubiquitination (Fig. 1B) .
Collectively, these data demonstrate that TRAF6 is the most potent PIK3CA E3 ligase in the TRAF family. Our previous work showed that ubiquitination of PIK3CA by NEDD4L led to its degradation [12] . Here, we observed that coexpression of wild-type TRAF6 resulted in an elevated level of PIK3CA protein ( , which was further recapitulated by a good correlation between PIK3CA protein levels and TRAF6 expression levels (Fig. 1C ). These observations suggest that ubiquitination of PIK3CA by TRAF6 does not lead to PIK3CA proteolysis.
To characterize the ubiquitin linkage catalyzed by TRAF6, we generated a series of ubiquitin mutants, each carrying a single Lys-to-Arg mutation. We found that besides the K63R mutation, which usually blocks TRAF6-mediated polyubiquitination, K27R, K29R, and K33R mutations also led to decreases in PIK3CA polyubiquitination (Fig. 1D ). These results suggest that TRAF6 is able to link both typical and atypical ubiquitin chains to PIK3CA. This characteristic of TRAF6 catalyzed ubiquitination is not unprecedented, since similar observations were reported for TRAF6-mediated ubiquitination of some neurodegeneration-related proteins [18, 19] .
TRAF6 ubiquitinates the catalytic subunit of the PI3K heterodimer
Since the catalytic and regulatory subunits of PI3K form a heterodimer in vivo [8] , we asked whether TRAF6 could also ubiquitinate the individual regulatory subunit and the heterodimeric PI3K complex. We coexpressed TRAF6 with PIK3CA, PIK3R1 (p85a), or both and analyzed their ubiquitination states. TRAF6 showed a comparable E3 ligase activity toward PIK3CA (Fig. 2A, lane 2 ) and PI3K complex (Fig. 2A, lane 6 ) but had little activity toward PIK3R1 (Fig. 2A, lane 4) . These results suggest that PIK3R1 is not a suitable substrate for TRAF6 and that the formation of the PI3K complex does not affect PIK3CA ubiquitination. We also analyzed the E3 ligase activity of TRAF6 toward PIK3CB, another ubiquitiously expressed PI3K catalytic subunit that plays a more important role than PIK3CA in PTEN-deficient tumor cells [20] . Similarly, both individual PIK3CB and the PIK3CB-PIK3R1 complex could be efficiently ubiquitinated by TRAF6 (Fig. 2B) , suggesting that TRAF6 is a general E3 ubiquitin ligase for PI3K catalytic subunits.
PIK3CA interacts with TRAF6 in vivo
The fact that TRAF6 catalyzes PIK3CA ubiquitination presumes that the two proteins may be associated in vivo. We coexpressed the two proteins and tested their interaction by coimmunoprecipitation experiments. We found that TRAF6 proteins were clearly detected in PIK3CA immunoprecipitates (Fig. 3A , lane 2), whereas PIK3R1 alone was not able to immunoprecipitate TRAF6 (Fig. 3A, lane 3) . The detection of a weak TRAF6 band from PIK3R1 immunoprecipitates was probably due to the association of the overexpressed PIK3R1 with endogenous PIK3CA, which then pulled down TRAF6 (Fig. 3A, lane 3) . To confirm these results, we did reciprocal coimmunoprecipitation. As expected, both PIK3CA and the PIK3CA-PIK3R1 complex, but not individually expressed PIK3R1, were coimmunoprecipitated with TRAF6 (Fig. 3B) . In addition, the E3 ligase activity of TRAF6 was not necessary for the interaction with PIK3CA, since two inactive TRAF6 mutants manifested similar binding ability to PIK3CA (Fig. 3C) .
We next sought to narrow down the domains responsible for the interaction. We coexpressed fulllength TRAF6 and individual domains of PIK3CA in HEK293T cells and examined their interactions (Fig. 3D) . We observed that the kinase domain and adapter-binding domain (ABD) of PIK3CA efficiently pulled down TRAF6, whereas the helical domain had a relatively low efficiency (Fig. 3E) . The Ras-binding domain (RBD) and C2 domain had little to no ability of TRAF6 binding (Fig. 3E) . We also observed that the ubiquitination of the individual domains of PIK3CA was positively correlated with their TRAF6-binding capabilities (Fig. 3F) .
We also examined the interaction between individual domains of TRAF6 and full-length PIK3CA (Fig. 3G) . Previous work suggested that the TRAF6 C-terminal domain plays a major role in mediating protein-protein interaction by recognizing a conserved Pro-X-Glu-X-X-aromatic/acidic residue motif [21] . Surprisingly, none of the individual domains of TRAF6 showed strong binding to PIK3CA (Fig. 3H) . We analyzed the protein sequence of PIK3CA and found no perfectly matched TRAF6-binding motif, which explains the relatively weak interaction between PIK3CA and the TRAF6 C-terminal domain. Next, we examined the binding of full-length PIK3CA to the TRAF6 fragment containing both coiled-coil and Cterminal domains (aa.281-522). We found that the TRAF6 aa.281-522 fragment has a similar binding capability to PIK3CA compared with full-length TRAF6 (Fig. S1 ). Since the coiled-coil domain is required for the formation of a trimeric TRAF complex [22] , our results suggest that trimerized TRAF6 C-terminal domain is responsible for the binding of PIK3CA.
Deregulated TRAF6 overexpression dramatically enhances PI3K activation
The upregulation of TRAF6 mRNA was observed in multiple human malignancies according to the Oncomine database (Fig. 4A) [23] and previous studies [24] [25] [26] [27] [28] . Gained TRAF6 gene copy number is also observed in human lung cancers [29] . Consistently, five out of nine human lung cancer cell lines that we examined showed increased levels of TRAF6 protein compared with that of BEAS-2B, a cell line derived from human bronchial epithelial cells (Fig. 4B) . Based on these observations, we next sought to answer the physiological significance for increased TRAF6 expression. We stably overexpressed TRAF6 or GFP in BEAS-2B cells, which have a low endogenous TRAF6 level (Fig. 4B ) and then tested their responses to serum stimulation. The cells were depleted of serum for 24 h, and then stimulated with serum for different duration times. Phosphorylation of AKT at T308 and S473 residues, two well-accepted readouts for PI3K activation [1] , was measured by western blot analysis. We found that, compared with GFP control, TRAF6 overexpression led to a dramatic increase in AKT phosphorylation at both T308 and S473 residues after serum treatment (Fig. 4C) .
We next tested whether these cells are more resistant to apoptosis under low serum challenges. We found that TRAF6 overexpression inhibited the cleavage of PARP and caspase-3, two hallmarks of apoptosis, under low serum conditions (Fig. 4D) . These effects were very likely fulfilled through enhanced PI3K activation, as an overall increase in phosphorylated AKT was observed in TRAF6-overexpressing cells (Fig. 4D) . Under serum concentrations of 1% and 2.5%, AKT proteins has been clearly phosphorylated in TRAF6-overexpressing cells but kept largely unphosphorylated in control cells. These results were further confirmed by the examination the phosphorylation states of FOXO1/3a proteins, which are representative downstream substrates of AKT. A remarkable increase in phosphorylated FOXO1/3a proteins was observed in TRAF6-overexpressing cells (Fig. 4D) . These data suggest a positive role of TRAF6 in regulating PI3K activation and inhibiting apoptosis.
In addition, we measured the growth rates of GFPor TRAF6-overexpressing BEAS-2B cells. Although the cell numbers did not show an obvious difference (Fig. 4E) , the sizes of TRAF6-overexpressing cells were dramatically larger than control (Fig. 4F) . The increase in the sizes of TRAF6-overexpressing cells was further revealed by a higher cell confluence under the same growth conditions (Fig. 4G and Fig. S2 ). Since AKT plays an important role in controlling cell size and nutrient uptake [30, 31] , the increase in the cell size caused by TRAF6 overexpression reflects an overactivation of PI3K-AKT signaling. In addition, TRAF6 overexpression led to higher colony formation ability revealed by soft agar analysis (Fig. 4H,I ).
TRAF6 ubiquitinates PIK3CA under serum stimulation
We next sought to determine the temporal regulation of PIK3CA by TRAF6. We immunoprecipitated the endogenous PIK3CA proteins from both GFP-and TRAF6-overexpressing BEAS-2B cells treated with or without serum and examined their ubiquitination states using an anti-ubiquitin antibody. In GFP-overexpressing cells, PIK3CA was ubiquitinated under serum present condition, whereas in TRAF6-overexpressing cells, we observed the ubiquitination signals under both serum absent and present conditions (Fig. 5A ). These observations suggest that TRAF6 overexpression results in a dysregulation of PIK3CA ubiquitination and activation, supported by a high level of phosphorylated AKT and FOXO1/3a under serum deprivation (Fig. 5A compares lane 3 with lane  1) . We also immunoprecipitated the endogenous TRAF6 proteins from H157 cells, which have a relatively high level of TRAF6 expression, and analyzed their interaction with endogenous PIK3CA protein.
We found that the two proteins were associated in vivo, but polyubiquitination of PIK3CA was only seen under serum present condition (Fig. 5B) .
Next, we analyzed the formation of PIK3CA-containing signaling complexes by gel filtration chromatography (Fig. 5C) . We found that, following serum stimulation, only a very small fraction of PIK3CA in cells was eluted out at high-molecularweight fractions, where multiprotein signaling complexes were supposed to be located [32] . These observations suggest that only a small fraction of PIK3CA proteins in cells are involved in the formation of the signaling complex. Therefore, it is plausible that a small amount of ubiquitinated PIK3CA is enough to exert a significant effect on RTK-mediated signaling transduction.
Discussion
Our previous work identified NEDD4L as the first PIK3CA E3 ubiquitin ligase that targets PIK3CA for proteasomal degradation under serum deprivation [12] . Here, we clarified the role of the second PIK3CA E3 ubiquitin ligase, TRAF6, in regulating PI3K activity. In contrast to NEDD4L, overexpression of TRAF6 increases the stability of PIK3CA protein and promotes PI3K activation (Fig. 5D ). Considering the fact that TRAF6 was also reported to promote AKT ubiquitination and activation in response to growth factor stimulation [33] , it is conceivable that ubiquitination of both proteins by TRAF6 plays a synergistic role in promoting PI3K-AKT signaling (Fig. 5D) .
Mechanically, how TRAF6 promotes PIK3CA activation is still not well understood. However, the following speculations may be involved. First, by interaction with TRAF6, more PIK3CA proteins can be recruited to the membrane-proximal region and access to their substrates embedded in the lipid bilayer. Second, ubiquitination of PIK3CA by TRAF6 promotes PIK3CA protein stability (Fig. 1C) . Third, positively charged ubiquitin molecules may promote PIK3CA membrane localization by interacting with the negatively charged lipid bilayer.
Many TNFR members such as CD40, OX40, and RANK directly or indirectly promote the activation of PI3K-AKT signaling in immune cells, in which TRAF proteins were thought to be required [34] . Our study provides a mechanistic clue of how TRAF6 bridges TNFR and PI3K-AKT signaling. TRAF6 very likely functions as an adaptor to recruit PI3K to the TNFRcontaining signalosomes assembled in the membraneproximal regions and then enhances PI3K activity by ubiquitinating it.
Compared with TRAF6, TRAF5 and TRAF2 showed weak E3 ubiquitin ligase activities toward PIK3CA (Fig. 1A) . However, our study does not exclude the possibility that TRAF5 and TRAF2 also affect PI3K activation, although likely to a lesser extent. Interestingly, TRAF5 and TRAF2 overexpression also led to an increase in PIK3CA protein levels (Fig. 1A) , suggesting partially overlapping roles of these two proteins with TRAF6. It is possible that there are cell types expressing a high level of TRAF5 or TRAF2 protein, which would allow for stronger PIK3CA ubiquitination activities to manifest an obvious effect on PI3K activation. 
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